HighTower Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

HighTower Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$1K	–	2631
2019 Q3	$1K	Buy	+1,000	New	+$3.41K	﹤0.01%	2403

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

HighTower Advisors's GNCA Position: Q2 2022 in Review

HighTower Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 212,260 shares — an estimated $266K sold.

HighTower Advisors first reported a position in GNCA in Q1 2018 and held it in 17 quarters. The position peaked at $666K in Q2 2019. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

HighTower Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
HighTower Advisors sold 212,260 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $266K.
HighTower Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 17 quarters.
HighTower Advisors's Genocea Biosciences, Inc. position peaked at $666K in Q2 2019.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.